WO1996016652A3 - Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections - Google Patents

Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections Download PDF

Info

Publication number
WO1996016652A3
WO1996016652A3 PCT/GB1995/002790 GB9502790W WO9616652A3 WO 1996016652 A3 WO1996016652 A3 WO 1996016652A3 GB 9502790 W GB9502790 W GB 9502790W WO 9616652 A3 WO9616652 A3 WO 9616652A3
Authority
WO
WIPO (PCT)
Prior art keywords
rifabutin
atovaquone
treatment
combination
pneumocystis carinii
Prior art date
Application number
PCT/GB1995/002790
Other languages
French (fr)
Other versions
WO1996016652A2 (en
Inventor
John Charles William Comley
Original Assignee
Wellcome Found
John Charles William Comley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found, John Charles William Comley filed Critical Wellcome Found
Priority to JP8517131A priority Critical patent/JPH10509722A/en
Priority to AU39871/95A priority patent/AU3987195A/en
Priority to EP95938501A priority patent/EP0794776A2/en
Publication of WO1996016652A2 publication Critical patent/WO1996016652A2/en
Publication of WO1996016652A3 publication Critical patent/WO1996016652A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to combinations of atovaquone and rifabutin, their use in the treatment and prophylaxis of infections caused by P.carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and rifabutin are administered in a potentiating ratio so that they act in synergy.
PCT/GB1995/002790 1994-11-29 1995-11-29 Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections WO1996016652A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8517131A JPH10509722A (en) 1994-11-29 1995-11-29 Use of rifabutin in the treatment of Pneumocystis carinii infection and combination of rifabutin with atovaquone
AU39871/95A AU3987195A (en) 1994-11-29 1995-11-29 Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections
EP95938501A EP0794776A2 (en) 1994-11-29 1995-11-29 Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424013A GB9424013D0 (en) 1994-11-29 1994-11-29 Medicaments
GB9424013.2 1994-11-29

Publications (2)

Publication Number Publication Date
WO1996016652A2 WO1996016652A2 (en) 1996-06-06
WO1996016652A3 true WO1996016652A3 (en) 1996-08-15

Family

ID=10765105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/002790 WO1996016652A2 (en) 1994-11-29 1995-11-29 Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections

Country Status (5)

Country Link
EP (1) EP0794776A2 (en)
JP (1) JPH10509722A (en)
AU (1) AU3987195A (en)
GB (1) GB9424013D0 (en)
WO (1) WO1996016652A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016010799A (en) 2014-02-19 2017-01-23 Texas A & M Univ Sys Compositions and methods for drug sensitization of parasites.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012164A1 (en) * 1992-11-26 1994-06-09 The Wellcome Foundation Limited Combination of atovaquone with proguanil for the treatment of protozoal infections
WO1994014426A1 (en) * 1992-12-24 1994-07-07 The Wellcome Foundation Limited Atovaquone pharmaceutical compositions
WO1994025038A1 (en) * 1993-05-05 1994-11-10 Palo Alto Medical Foundation Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012164A1 (en) * 1992-11-26 1994-06-09 The Wellcome Foundation Limited Combination of atovaquone with proguanil for the treatment of protozoal infections
WO1994014426A1 (en) * 1992-12-24 1994-07-07 The Wellcome Foundation Limited Atovaquone pharmaceutical compositions
WO1994025038A1 (en) * 1993-05-05 1994-11-10 Palo Alto Medical Foundation Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMERICAN SOCIETY FOR MICROBIOLOGY. HUMAN RETROVIRUSES AND RELATED INFECTIONS;2ND NATIONAL CONFERENCE, WASHINGTON, D.C., USA, JANUARY 29-FEBRUARY 2, 1995. IV+177P. AMERICAN SOCIETY FOR MICROBIOLOGY (ASM): WASHINGTON, DC, USA. 0 (0). 1995. 109. *
ARAUJO FG ET AL: "Rifabutin is active in murine models of toxoplasmosis.", ANTIMICROB AGENTS CHEMOTHER, MAR 1994, 38 (3) P570-5, UNITED STATES, XP002002492 *
COMLEY JC ET AL: "Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.", ANTIMICROB AGENTS CHEMOTHER, APR 1995, 39 (4) P806-11, UNITED STATES, XP002002493 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; COMLEY J C W ET AL: "Synergistic effect of rifabutin on the prophylactic activity of atovaquone against pneumocystis carinii (PCP) in the SCID mouse", XP002002496 *
PETERS BS ET AL: "Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.", DRUG SAF, JUN 1994, 10 (6) P439-54, NEW ZEALAND, XP002002494 *
WEISER J ET AL: "Preliminary results of a broad-based primary prophylaxis phase I study in HIV-infected persons wtih CD4 counts less than or equal to 200/mm3.", INT CONF AIDS, JUL 19-24 1992, 8 (2) PB133 (ABSTRACT NO. POB 3278), XP002002495 *

Also Published As

Publication number Publication date
AU3987195A (en) 1996-06-19
JPH10509722A (en) 1998-09-22
GB9424013D0 (en) 1995-01-18
WO1996016652A2 (en) 1996-06-06
EP0794776A2 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
MY111177A (en) Flavour-masked pharmaceutical compositions
CA2319201A1 (en) Celecoxib compositions
BR9911072A (en) Preparations for the application of anti-inflammatory agents, especially antiseptics and / or agents that promote wound healing in the lower respiratory tract
CA2105487A1 (en) Antiviral nucleoside combination
CA2124677A1 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
NZ241211A (en) 16alpha,17alpha-alkylidenedioxy-11b,21-dihydroxypregan -4-ene-3,20-dione derivatives substituted by halogen in either or both of the 6alpha- or the 9alpha- position; pharmaceutical compositions, methods of preparation and treatment
CA2293470A1 (en) Benzimidazole derivatives
CA2024916A1 (en) Respiratory disorder medicaments comprising salmeterol and fluticasone propionate
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
NZ241210A (en) 16alpha,17alpha-butylidenedioxy-11b, 21-dihydroxypregn-4-ene-3,20-dione derivatives substituted in either or both the 6alpha- and 9alpha- positions by fluorine; pharmaceutical compositions, methods of preparation and treatment
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
EP1393734A4 (en) Drugs for intestinal diseases
ES2188582T3 (en) THE USE OF RANITIDINE-BISMUTE CITRATE IN COMBINATION WITH CLARITROMYCIN OR CLARITROMYCIN AND TETRACICLINE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT GASTROINTESTINAL DISORDERS.
MX9603596A (en) Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds.
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
WO1999026589A3 (en) Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
ATE114244T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FLUTICASONE PROPIONATE AND OXIKONAZOLE OR ITS SALT FOR LOCAL APPLICATION.
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
WO1996022305A3 (en) Modified peptides
CA2150234C (en) Combination of atovaquone with proguanil for the treatment of protozoal infections
Afifi et al. High dose ascorbic acid in the management of thalassaemia leg ulcers—a pilot study
WO2003018535A3 (en) Novel aminobenzoephenones
CA2385755A1 (en) Prevention of colorectal cancer
WO1996016652A3 (en) Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 817880

Date of ref document: 19970501

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995938501

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995938501

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995938501

Country of ref document: EP